Author/Authors :
Tarban, N Department of Biology - Kish International Campus - University of Tehran, Kish , Habibi Rezaei, M School of Biology - College of Science - University of Tehran , Shafifar, M Department of Virology - School of Public Health - Tehran University of Medical Sciences , Mohammad hosayni, M Department of immunology - shahed university - school of medicine, Tehran , Rezaee, S A Immunology Research Center - School of Medicine - Mashhad University of Medical Sciences , Jazayeri, S M School of Biology - College of Science - University of Tehran , Norouzi, M School of Biology - College of Science - University of Tehran
Abstract :
Background and Aims: Human lymphotropic virus type-1 (HTLV-1) causes various
diseases in human such as adult T-cell leukemia/lymphoma (ATLL) and HTLV-1 associated
myelopathy/tropical spastic paraperesis (HAM / TSP). The main goal of this study was to
compare Iranian protease subtypes structure of this virus (HTLV-1) to samples collected from
other part of world in order to understand their differences.
Materials and Methods: During 1394 -1395, 10 blood samples taken from HTLV-1 virus
infected individuals. Samples were tested using polymerase chain reaction (PCR) process.
The obtained products were sequenced and phylogenetic analysis was performed. The second
and third structures of these sequences were determined using a specialized websites.
Results: The Iranian samples were completely exposed in to the cluster of Cosmopolitan
subtype. The result of first structure alignment of protease protein in different subtypes of the
virus, revealed some differences in the gene of interest. The conversion of the first structure
to second and third structures, pairwise and multiple alignment showed no significant
difference in the protease protein conformation.
Conclusions: The comparison of HTLV-1 virus protease protein from Iran and other
sequences in the world which were obtained from GenBank showed no significant
dissimilarity. This dissimilarity helps to design a plan for production of the drug. Therefore,
future studies can target a part of the protein and generalize a treatment for all subtypes
circulating. This comparison has beneficiary effect in making the right medication that inhibit
the subtypes of the virus emerging during the course of treatment.